Howard Burris, MD, FACP, FASCO: Adoption of Anticancer Biosimilars

Howard Burris, MD, FACP, FASCO, president of clinical operations and chief medical officer of Sarah Cannon Research Institute, discusses the adoption of oncology biosimilars.


So the biosimilars, I think, will be rapidly adopted. We’re in a world where the new cancer drugs really sort of came along in a flood in the 1990s, so we’ve had experience with generics in that regard. We’ve had oral generics coming along for a while. I think the biosimilars are actually coming from some of the larger manufacturers. The idea of transitioning to that, I think, will flow well.